Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | BRS3 | P32247 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800046 | 0.94 | TRPV1 (0.47) | TRPV1PDE10ARAB9AFFAR1CACNA1B | |
| SCHEMBL1798091 | 0.92 | TRPV1 (0.44) | TRPV1PDE10ABRS3RAB9AFFAR1 | |
| SCHEMBL12350136 | 0.89 | TRPV1 (0.48) | TRPV1PDE10ABRS3RAB9ANPC1 | |
| SCHEMBL12350135 | 0.89 | ALDH1A1 (0.43) | TRPV1BRS3RAB9AFFAR1NPC1 | |
| SCHEMBL12350130 | 0.88 | TRPV1 (0.47) | TRPV1PDE10ARAB9ANPC1NTRK1 | |
| SCHEMBL12359243 | 0.87 | TRPV1 (0.45) | TRPV1PDE10ARAB9ANPC1NTRK1 | |
| SCHEMBL1795333 | 0.87 | TRPV1 (0.45) | TRPV1PDE10ARAB9ANPC1NTRK1 | |
| SCHEMBL12350139 | 0.84 | TRPV1 (0.47) | TRPV1BRS3NTRK1NTRK2 | |
| SCHEMBL12350338 | 0.82 | TRPV1 (0.47) | TRPV1FFAR1SCDHTT | |
| SCHEMBL1798998 | 0.82 | TRPV1 (0.44) | TRPV1BRS3RAB9ANPC1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190364-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | TRPV1 29/4885PDE10A 1432/4885BRS3 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.